TVTXTravere Therapeutics, Inc.
$52.12+110% 1Y
$52.12
$23.9052 weeks$67.51
Is the price fair?
What TVTX's price assumes
Travere Therapeutics, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 9.33× revenue.
9.33
Price / sales · no P/E: the last twelve months did not end in a profit
- Price / book
- 225
Price / book · as of 2026-Q2
Details›
- Price / bookas of 2026-Q2
- 225
- EV / EBIToperating margin −6.8%: the multiple describes the denominator
- not meaningful
- Market capitalisation
- $5.49B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
On our screens:Most shorted stocks